Gkiourtzis Nikolaos, Stoimeni Anastasia, Michou Panagiota, Moutafi Maria, Cheirakis Konstantinos, Christakopoulos Aristeidis, Glava Agni, Panagopoulou Paraskevi, Tsigaras Georgios, Galli-Tsinopoulou Assimina, Christoforidis Athanasios, Tramma Despoina
Aristotle University of Thessaloniki, Faculty of Health Sciences, School of Medicine, 4th Department of Pediatrics, Papageorgiou General Hospital, Thessaloniki, Greece.
Aristotle University of Thessaloniki, Faculty of Health Sciences, School of Medicine, Program of Postgraduate Studies Adolescent Medicine and Adolescent Health Care, Thessaloniki, Greece.
J Bras Nefrol. 2025 Oct-Dec;47(4):e20240236. doi: 10.1590/2175-8239-JBN-2024-0236en.
Diabetic kidney disease (DKD) is a major complication of type 1 diabetes mellitus (T1D). In clinical practice, albuminuria and reduced estimated glomerular filtration rate (eGFR) are the main characteristics of DKD. Later studies revealed that interstitial damage is also observed as DKD occurs. Therefore, the application of a biomarker for early DKD detection was critical. This systematic review aimed to summarize the literature about the prognostic role of cystatin C in kidney injury in children and adolescents with T1D.
From inception until September 24, 2024, an extensive literature search through major databases (MEDLINE/PubMed, Cochrane Library, and Scopus) was carried out to investigate the prognostic role of cystatin C in kidney injury in pediatric patients with T1D. The mean difference was used for continuous outcomes with 95%CI. A p < 0.05 was considered statistically significant. A quality assessment of included studies was conducted using the Newcastle-Ottawa Scale.
We included eleven studies with 2199 participants in this systematic review. The meta-analysis included four studies. No statistically significant difference was observed in serum cystatin C levels between patients with T1D and the control group.
Although individual studies showed some benefit of using serum cystatin C for the prognosis of DKD in pediatric patients with T1D, the meta-analysis of included studies reached no statistical significance. Future clinical studies should focus on the prognostic role of cystatin C (serum and urinary) in identifying kidney injury in pediatric patients with T1D.
糖尿病肾病(DKD)是1型糖尿病(T1D)的主要并发症。在临床实践中,蛋白尿和估算肾小球滤过率(eGFR)降低是DKD的主要特征。后来的研究表明,随着DKD的发生也会观察到间质损伤。因此,应用生物标志物进行DKD早期检测至关重要。本系统评价旨在总结关于胱抑素C在T1D儿童和青少年肾损伤中的预后作用的文献。
从开始到2024年9月24日,通过主要数据库(MEDLINE/PubMed、Cochrane图书馆和Scopus)进行了广泛的文献检索,以研究胱抑素C在T1D儿科患者肾损伤中的预后作用。连续结局采用均数差值及95%置信区间。p<0.05被认为具有统计学意义。使用纽卡斯尔-渥太华量表对纳入研究进行质量评估。
本系统评价纳入了11项研究,共2199名参与者。荟萃分析纳入了4项研究。T1D患者与对照组之间的血清胱抑素C水平未观察到统计学显著差异。
尽管个别研究显示使用血清胱抑素C对T1D儿科患者的DKD预后有一定益处,但纳入研究的荟萃分析未达到统计学意义。未来的临床研究应关注胱抑素C(血清和尿液)在识别T1D儿科患者肾损伤中的预后作用。